Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11
- PMID: 12384538
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11
Abstract
Combining anticancer drugs with different mechanisms of action has the potential to enhance antitumor effect. CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly effective in the treatment of a variety of cancers. However, its clinical usage is often complicated by late diarrhea. A number of studies have shown that cyclooxygenase (COX)-2 is overexpressed in many forms of human tumors, suggesting that COX-2 inhibition may be useful in the treatment of cancer. In this study, we used two mouse tumor models (HT-29 and colon-26 cells) to evaluate the effect of combining CPT-11 with celecoxib on tumor growth. We also assessed the involvement of COX-2 in the pathogenesis of CPT-11-induced late diarrhea using a rat model. Results indicate that celecoxib enhances the antitumor effect of CPT-11 and reduces the severity of late diarrhea in a dose-dependent manner. The extended benefits of combining celecoxib with CPT-11 may significantly improve the outcome of cancer patients.
Similar articles
-
Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.Cancer Res. 2003 Oct 15;63(20):6726-34. Cancer Res. 2003. PMID: 14583467
-
Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.Cancer Res. 2002 Nov 15;62(22):6706-11. Cancer Res. 2002. PMID: 12438270
-
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.FASEB J. 2001 Dec;15(14):2742-4. doi: 10.1096/fj.01-0299fje. Epub 2001 Oct 15. FASEB J. 2001. PMID: 11606477
-
Irinotecan, cisplatin/carboplatin, and COX-2 inhibition in small-cell lung cancer.Oncology (Williston Park). 2003 Jul;17(7 Suppl 7):22-6. Oncology (Williston Park). 2003. PMID: 12886870 Review.
-
Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme.Oncology (Williston Park). 2003 May;17(5 Suppl 5):15-24. Oncology (Williston Park). 2003. PMID: 12800601 Review.
Cited by
-
Nutritional treatment with an immune-modulating enteral formula alleviates 5-fluorouracil-induced adverse effects in rats.PLoS One. 2019 Nov 26;14(11):e0225389. doi: 10.1371/journal.pone.0225389. eCollection 2019. PLoS One. 2019. PMID: 31770400 Free PMC article.
-
Potency of non-steroidal anti-inflammatory drugs in chemotherapy.Mol Clin Oncol. 2015 Jan;3(1):3-12. doi: 10.3892/mco.2014.446. Epub 2014 Oct 16. Mol Clin Oncol. 2015. PMID: 25469262 Free PMC article.
-
Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin.Pharm Res. 2005 Nov;22(11):1954-63. doi: 10.1007/s11095-005-6096-4. Epub 2005 Aug 13. Pharm Res. 2005. PMID: 16086226
-
Human multidrug resistance associated protein 4 confers resistance to camptothecins.Pharm Res. 2005 Nov;22(11):1837-53. doi: 10.1007/s11095-005-7595-z. Pharm Res. 2005. PMID: 16132345
-
Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.Front Oncol. 2011 Dec 13;1:52. doi: 10.3389/fonc.2011.00052. eCollection 2011. Front Oncol. 2011. PMID: 22649768 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials